{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:21:30Z","timestamp":1790896890813,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00277-017-3147-y","type":"journal-article","created":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T22:39:14Z","timestamp":1507588754000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma"],"prefix":"10.1007","volume":"97","author":[{"given":"Emilie","family":"Fargier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ranchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Guerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Safar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Hequet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Savouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Fronteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tomar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tournamille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9rane","family":"Schwiertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vantard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"3147_CR1","unstructured":"Monnereau A, Remontet L, Maynadi\u00e9 M, et al (2013) Lymphome folliculaire. In: Estim. Natl. L\u2019incidence Cancers En Fr. Entre 1980 2012 Partie 2\u2014H\u00e9mopathies Malignes. Institut de Veille Sanitaire, Saint Maurice (Fra), p 24\u201327"},{"key":"3147_CR2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116:3724\u20133734","journal-title":"Blood"},{"key":"3147_CR3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT et al (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122:981\u2013987","journal-title":"Blood"},{"key":"3147_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","volume":"88","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Marchetti M, Billio A et al (2013) SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 88:185\u2013192","journal-title":"Am J Hematol"},{"key":"3147_CR5","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v83\u2013v90","journal-title":"Ann Oncol"},{"key":"3147_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet Lond Engl 377:42\u201351","journal-title":"Lancet Lond Engl"},{"key":"3147_CR7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G et al (2011) Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 103:1799\u20131806","journal-title":"J Natl Cancer Inst"},{"key":"3147_CR8","doi-asserted-by":"crossref","unstructured":"Salles GA, Seymour JF, Feugier P, et al (2013) Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. In: Blood. New Orleans, p 21","DOI":"10.1182\/blood.V122.21.509.509"},{"key":"3147_CR9","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/bjc.2013.371","volume":"109","author":"O Shpilberg","year":"2013","unstructured":"Shpilberg O, Jackisch C (2013) Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 109:1556\u20131561","journal-title":"Br J Cancer"},{"key":"3147_CR10","unstructured":"F. Hoffmann-La Roche RCP MabThera SC. https:\/\/www.roche.fr\/content\/dam\/roche_france\/fr_FR\/doc\/Produits\/Mabthera\/MABTH1400IN_160526rcp.pdf . Accessed 11 Aug 2016"},{"key":"3147_CR11","unstructured":"Davies A, Mihaljevi B, Marcadal S, et al (2015) Comparison of subcutaneous and intravenous rituximab in the maintenance setting: updated safety results of the phase III SABRINA study in patients with follicular lymphoma. EHA Learning Center. https:\/\/learningcenter.ehaweb.org\/eha\/2015\/20th\/100828 . Accessed 4 Jan 2016"},{"key":"3147_CR12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","volume":"15","author":"A Davies","year":"2014","unstructured":"Davies A, Merli F, Mihaljevic B et al (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 15:343\u2013352","journal-title":"Lancet Oncol"},{"key":"3147_CR13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3111\/13696998.2014.914033","volume":"17","author":"S Rule","year":"2014","unstructured":"Rule S, Collins GP, Samanta K (2014) Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ 17:459\u2013468","journal-title":"J Med Econ"},{"key":"3147_CR14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10332-005-0047-5","volume":"4","author":"A Br\u00e9dart","year":"2005","unstructured":"Br\u00e9dart A, Dolbeault S (2005) \u00c9valuation de la qualit\u00e9 de vie en oncologie: I\u2014D\u00e9finitions et objectifs. Rev Francoph Psycho-Oncol 4:7\u201312","journal-title":"Rev Francoph Psycho-Oncol"},{"key":"3147_CR15","unstructured":"Department of Economics and Public Health Assessment (2012) Choices in methods for economic evaluation. https:\/\/www.has-sante.fr . Accessed 25 Sept 2015"},{"key":"3147_CR16","unstructured":"Coll\u00e8ge des \u00e9conomistes de la sant\u00e9 (CES) (2004) French guidelines for the economic evaluation of healthcare technologies: methodological recommendations 1\u201390"},{"key":"3147_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10198-011-0351-x","volume":"14","author":"J Chevalier","year":"2013","unstructured":"Chevalier J, de Pouvourville G (2013) Valuing EQ-5D using time trade-off in France. Eur J Health Econ HEPAC Health Econ Prev Care 14:57\u201366","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"key":"3147_CR18","first-page":"1","volume":"30","author":"J Rovira","year":"2011","unstructured":"Rovira J, Esp\u00edn J, Garc\u00eda L, Olry de Labry A (2011) The impact of biosimilars\u2019 entry in the EU market. Andal Sch Pub Health 30:1\u201383","journal-title":"Andal Sch Pub Health"},{"key":"3147_CR19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bulcan.2015.01.007","volume":"102","author":"V Lieutenant","year":"2015","unstructured":"Lieutenant V, Toulza \u00c9, Pommier M, Lortal-Canguilhem B (2015) Herceptin\u00ae (trastuzumab) par voie sous-cutan\u00e9e : une mini r\u00e9volution ? \u00c9tude pharmaco-\u00e9conomique. Bull Cancer (Paris) 102:270\u2013276","journal-title":"Bull Cancer (Paris)"},{"key":"3147_CR20","doi-asserted-by":"publisher","unstructured":"Cesarec A, Liki\u0107 R (2017) Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia. Appl Health Econ Health Policy 15:277-286. https:\/\/doi.org\/10.1007\/s40258-016-0285-7","DOI":"10.1007\/s40258-016-0285-7"},{"key":"3147_CR21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","volume":"28","author":"M Rummel","year":"2017","unstructured":"Rummel M, Kim TM, Aversa F et al (2017) Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol 28:836\u2013842","journal-title":"Ann Oncol"},{"key":"3147_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","volume":"28","author":"E Deconinck","year":"2010","unstructured":"Deconinck E, Miadi-Fargier H, Pen CL, Brice P (2010) Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. PharmacoEconomics 28:35\u201346","journal-title":"PharmacoEconomics"},{"key":"3147_CR23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","volume":"88","author":"M Witzens-Harig","year":"2009","unstructured":"Witzens-Harig M, Reiz M, Heiss C et al (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin\u2019s lymphoma: results of a prospective randomized controlled trial. Ann Hematol 88:51\u201357","journal-title":"Ann Hematol"},{"key":"3147_CR24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2013-04-498014","volume":"122","author":"ED Cock","year":"2013","unstructured":"Cock ED, Kritikou P, Tao S et al (2013) Time savings with rituximab subcutaneous (SC) injection vs rituximab intravenous (IV) infusion: final analysis from a time-and-motion study in 8 countries. Blood 122:1724\u20131724","journal-title":"Blood"},{"key":"3147_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.clinthera.2017.05.342","volume":"39","author":"J Mihajlovi\u0107","year":"2017","unstructured":"Mihajlovi\u0107 J, Bax P, van Breugel E et al (2017) Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther 39:1221\u20131232.e4. https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.342","journal-title":"Clin Ther"},{"key":"3147_CR26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","volume":"29","author":"S Olofsson","year":"2016","unstructured":"Olofsson S, Norrlid H, Karlsson E et al (2016) Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer\u2014an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast Edinb Scotl 29:140\u2013146","journal-title":"Breast Edinb Scotl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3147-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3147-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3147-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T23:32:07Z","timestamp":1603063927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3147-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3147"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3147-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}